Antibiotic use in the emergency department. III. The quinolones, new beta lactams, beta lactam combination agents, and miscellaneous antibiotics

Journal of Emergency Medicine

Volumn 14, Issue 4, 1996, Pages 483-496

  Schmidt, Joyce ^a   Pollack Jr , Charles V ^a  

^a MARICOPA MEDICAL CENTER   (United States)

Author keywords

aztreonam; beta lactam antibiotics; clavulanate; clindamycin; imipenem; infectious diseases; metronidazole; quinolone antibiotics; sulbactam; tazobactam; treatment; va ncomycin; vancomycin

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; CLAVULANIC ACID; CLINDAMYCIN; ENOXACIN; IMIPENEM; LOMEFLOXACIN; METRONIDAZOLE; NORFLOXACIN; OFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; SULBACTAM; SULTAMICILLIN; TAZOBACTAM; TICARCILLIN; TIMENTIN; VANCOMYCIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; CLINICAL FEATURE; COST BENEFIT ANALYSIS; DIARRHEA; DRUG MIXTURE; DRUG USE; EMERGENCY TREATMENT; GRAM NEGATIVE SEPSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; OTOTOXICITY; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; PSEUDOMONAS; RASH; VOMITING;

EID: 0030199136     PISSN: 07364679     EISSN: None     Source Type: Journal    
DOI: 10.1016/0736-4679(96)00085-6     Document Type: Article

References (101)

1. 1. Walker RC, Wright AJ. The fluoroquinolones. Symposium on antimicrobial agents. Part IV. Mayo Clin Proc. 1991;66:1249-59.
2. 2. Anon: Enoxacin: a new fluoroquinolone. Med Lett Drugs Ther. 1992;34:103-5.
3. 3. Neu HC. Quinolone antimicrobial agents. Ann Rev Med. 1992; 43:465-86.
4. 4. Anon: Decreased susceptibility of Neisseria gonorrhoeae to fluoroquinolones - Ohio and Hawaii, 1992-1994. MMWR. 1994;43:325-327.
5. 5. Bitar N, Claes R, Van der Auwera P. Concentrations of ofloxacin in serum and cerebrospinal fluid of patients without meningitis receiving the drug intravenously and orally. Antimicrob Agents Chemother. 1989;33:1686-90.
6. 6. Modai J. Potential role of fluoroquinolones in the treatment of bacterial meningitis. Eur J Clin Microbiol Infect Dis. 1991; 10:291-5.
7. 7. Anon: Two new fluoroquinolones. Med Lett Drugs Ther. 1992; 34:58-60.
8. 8. Lode H, Hoffken G, Borner K, Koeppe P. Unique aspects of quinolone pharmacokinetics. Clin Pharm. 1989;16(suppl 1):S1-S4.
9. 9. Grubbs NC, Schultz HJ, Henry WK. et al. Ciprofloxacin vs. trimethoprim-sulfamethoxazole: treatment of community-acquired urinary tract infections in a prospective, controlled, double-blind comparison. Mayo Clin Proc. 1992;67:1163-8.
10. 10. Guibert J, Capron MH. Uncomplicated urinary tract infections: lomefloxacin vs. trimethoprim/sulfamethoxazole. J Int Med Res. 1992;20:467-74.
11. 11. Andriole VT. Use of quinolones in treatment of prostatitis and lower urinary tract infections. Eur J Clin Microbiol Infect Dis. 1991;10:342-50.
12. 12. Naber KG. Use of quinolones in urinary tract infections and prostatitis. Rev Infect Dis. 1989;11 (suppl 5):S1321-37.
13. 13. Hooper DC, Wolfson JS. Fluoroquinolone antimicrobial agents. N Engl J Med. 1991;324:384-94.
14. 14. Mogabgab WJ, Holmes B, Murray M, et al. Randomized comparison of ofloxacin and doxycycline for chlamydia and ureaplasma urethritis and cervicitis. Chemotherapy. 1990;36:70-6.
15. 15. CDC Sexually transmitted disease treatment guidelines, 1993. Natl Center for Prevention Svcs, CDC. 1993:54-80.
16. 16. Gentry LO. Therapy with newer oral β-lactam and quinolone agents for infections of the skin and skin structures: a review. Clin Infect Dis. 1992;14:285-97.
17. 17. Simon HB, Swartz MN. Chemotherapy for microbial diseases. In Rubenstein E, Federman DD, eds. Scientific American medicine. New York: Scientific American; 1992:7:XIV; 1-54.
18. 18. Anon: Ophthalmic ciprofloxacin. Med Lett Drugs Ther. 1991; 33:52-3.
19. 19. Leibowitz HM. Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis. Am J Opthalmol. 1991;112:29S-33S.
20. 20. Wadworth AN, Goa KL. Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1991;42:1018-60.
21. 21. Norrby SR. Side effects of quinolones: comparisons between quinolones and other antibiotics. Eur J Clin Microbiol Infect Dis. 1991;10:378-83.
22. 22. Fluoroquinolone antimicrobial drugs. AMA Drug Evaluations. 1993;8:1-14.
23. 23. Neu HC. Aztreonam activity, pharmacology, and clinical uses. Am J Med. 1990;88:2S-6S.
24. 24. Sykes RB, Bonner DP. Aztreonam: the first monobactam. Am J Med. 1985;78:2-10.
25. 25. Modai J, Vittecoq D, Decazes JM, Wolff M, Meulemans A. Penetration of aztreonam into cerebrospinal fluid of patients with bacterial meningitis. Antimicrob Agents Chemother. 1986;29:281-3.
26. 26. Brewer NS, Hellinger WC. The monobactams. Mayo Clin Proc. 1991;66:1152-7.
27. 27. Cunha BA. Aztreonam. Urology. 1993;41:249-58.
28. 28. Lentnek AL, Williams RR. Aztreonam in the treatment of gram-negative bacterial meningitis. Rev Infect Dis. 1991; 13(suppl 7):S586-90.
29. 29. Cook JL. Gram-negative bacillary pneumonia in the nosocomial setting: role of aztreonam therapy. Am J Med. 1990; 88:34S-37S.
30. 30. Sion ML, Pyrpasopoulos M, Nicolaidis P, Papagianni C, Tsurutsoglu C. Efficacy and safety of aztreonam in the treatment of patients with renal failure. Rev of Infect Dis. 1991;13(suppl 7):S652-4.
31. 31. Anon: Other beta-lactam antimicrobial agents. AMA Drug Evaluations. 1993;3:1-4.
32. 32. Hellinger WC, Brewer NS. Imipenem. Mayo Clin Proc. 1991; 66:1074-81.
33. 33. Neu HC. Other β-lactam antibiotics. In: Mandell R, Douglas GR Jr, Bennet JE, eds. Principles and Practice of Infectious Disease. New York: Churchill Livingston; 1990:264-71.
34. 34. Modai J, Vittecoq D, Decazes JM, Meulemans A. Penetration of imipenem and cilastatin into cerebrospinal fluid of patients with bacterial meningitis. Antimicrob Chemother. 1985; 16:751-5.
35. 35. Haimi-Cohen Y, Amir J, Weinstock A, Varsano I. The use of imipenem-cilastatin in neonatal meningitis caused by Citrobacter diverusu. Acta Paediatr. 1993;82:530-2.
36. 36. Wong VK, Wright HT, Ross LA, et al. Imipenem-cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J. 1991;10:122-5.
37. 37. Rolston KVI, Berkey P, Boday GP, et al. A comparison of imipenem to ceftazidine with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med. 1992; 152:283-91.
38. 38. Solomkin JS, Dellinger EP, Christou NV, Busuttil RW. Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections. Ann Surg. 1990;212:581-91.
39. 39. Calandra G, Lydick E, Carrigan J, Weiss L, Guess H. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin. Am J Med. 1988;84:911-18.
40. 40. Rolinson GN. Evolution of β-lactamase inhibitors. Rev Infect Dis. 1991;13(suppl9):S727-32.
41. 41. Todd PA, Benfield P. Amoxicillin/clavulanic acid: an update of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1990;39:264-307.
42. 42. Pichichero M, Aronovitz GH, Gooch WM, et al. Comparison of cefuroxime axetil, cefaclor, and amoxicillin-clavulanate potassium suspensions in acute otitis media in infants and children. South Med J. 1990;83:1174-7.
43. 43. Wright AJ, Wilkowske CJ. The penicillins. Mayo Clin Proc. 1991;66:1047-63.
44. 44. Abramowicz M. Handbook of antimicrobial therapy, revised edition. New Rochelle, New York: Med Lett Drugs Ther, 1992.
45. 45. Roselle GA, Bode R, Hamilton B, et al. Clinical trial of the efficacy and safety of ticarcillin and clavulanic acid. Antimicrob Agents Chemother. 1985;27:291-6.
46. 46. Pankey GA. Diagnosis and treatment of skin and soft tissue infections: clinical experience with ticarcillin disodium-clavulanate potassium. Pharmacotherapy. 1991;11:90S-98S.
47. 47. Pastorek JG, Sanders CV Jr. Antibiotic therapy for post cesarean endomyometritis. Rev Infect Dis. 1991;13(suppl 9): S752-7.
48. 48. Faro S, Hammill HA, Maccato M, Martens M. Ticarcillin/ clavulanate for treatment of postpartum endometritis. Rev Infect Dis. 1991;13(suppl 9):S758-62.
49. 49. Lucas MJ, Cox SM, Roark ML, Cunningham FG. Ticarcillin/ clavulanate in the treatment of pelvic infections. J Reprod Med. 1990;35:343-7.
50. 50. Meunier F, Snoeck R, Lagast H, Woussen F, Klastersky J. Empirical antimicrobial therapy with Timentin plus amikacin in febrile granulocytopenic cancer patients. J Antimicrob Chemother. 1986;17:195-201.
51. 51. Segreti J, Kapell KS, Trenholme GM. In vitro activity of beta-lactam drugs and sulbactam against Chlamydia trachomatis. Diagn Microbiol Infect Dis 1992;15:371-3.
52. 52. Crombleholme WR, Ohm-Smith M, Robbie MO, DeKay V, Sweet RL. Ampicillin/sulbactam vs. metronidazole-gentamicin in the treatment of soft tissue pelvic infection. Am J Obstet Gynecol. 1987;156:507-12.
53. 53. Wald E, Reilly JS, Bluestone CD, Chiponis D. Sulbactam/ ampicillin in treatment of acute epiglottis in children. Rev Infect Dis. 1986;8(suppl 5):S617-19.
54. 54. Anon: Ampicillin/sulbactam (Unasyn). Med Lett Drugs Ther. 1987;29:79-81.
55. 55. Tan JS, Wishnow RM, Talan DA, Duncanson FP, Norden CW. Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam vs. ticarcillin-clavulanate. Antimicrob Agents Chermother. 1993;37:1580-6.
56. 56. Anon: Piperacillin/tazobactam. Med Lett Drugs Ther. 1994; 36:7-9.
57. 57. Reeves DS, Holt HA, Bywater MJ, MacGowan AP. The activity of piperacillin/tazobactam against clinical isolates collected in 20 UK centers and the design of a disc test for susceptibility testing. J Antimicrob Chemother. 1993;32:51-61.
58. 58. Sweet RL, Roy S, Faro S, et al. Piperacillin and tazobactam vs. clindamycin and gentamicin in the treatment of hospitalized women with pelvic infection. Obstet Gynecol. 1994;83:280-6.
59. 59. Polk HC, Fink MP, Laverdiere M, et al. Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra-abdominal infection. Am Surg. 1993;59:598-605.
60. 60. Brismar B, Malmborg AS, Tunevall G, et al. Piperacillin-tazobactam vs. imipenem-cilastatin for treatment of intra-abdominal infection. Antimicrob Agents Chemother. 1992;36:2766-73.
61. 61. Niinikoski J, Havia T, Alhava E, et al. Piperacillin/tazobactam vs. imipenem/cilastatin in the treatment of intra-abdominal infections. Surg Gynecol Obstet. 1993;176:255-61.
62. 62. Wilhelm MP. Vancomycin. Mayo Clin Proc. 1991;66:1165-70.
63. 63. Fekety R. Vancomycin and teicoplanin. In Mandell R, Douglas GR Jr., Bennet JE, eds. Principles and Practice of Infectious Disease. New York: Churchill Livingston Inc.: 1990:317-23.
64. 64. Levine JF. Vancomycin: a review. Med Clin N Am 1987; 71:1135-45.
65. 65. Anon: Miscellaneous antibacterial drugs. AMA Drug Evaluations. 1993;9:1-23.
66. 66. Watanakunakorn C. Treatment of infections due to methicillin-resistant Staphylococcus aureus. Ann Intern Med. 1982; 97:376-8.
67. 67. Gump DW. Vancomycin for treatment of bacterial meningitis. Rev Infect Dis. 1981(suppl 3);S289-92.
68. 68. Viladrich PF, Gudiol F, Linares J, et al. Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrob Agents Chemother. 1991;35:2467-72.
69. 69. Dajani AS, Bisno AL, Chung KJ, et al. Prevention of bacterial endocarditis: recommendations by the American Heart Association. JAMA. 1990;264:2919-22.
70. 70. Anon: The choice of antibacterial drugs. Med Lett Drugs Ther. 1992;34:49-56.
71. 71. European Organization for Research and Treatment of Cancer. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis. 1991;163:951-8.
72. 72. Oliva SL, Gugliemlmo BJ. Jacobs R. Pons VG. Failure of intravenous vancomycin and intravenous metronidazole to prevent or treat antibiotic-associated pseudomembranous colitis. J Infect Dis. 1989;159:1154-5.
73. 73. Sahai J, Healy DP, Garris R, Berry A, Polk RE. Influence of antihistamine pretreatment on vancomycin-induced red-man syndrome. J Infect Dis. 1989;160:876-81.
74. 74. Gatterer G. Spasmodic low back pain in a patient receiving intravenous vancomycin during continuous ambulatory peritoneal dialysis. Clin Pharm. 1984;3:87-9.
75. 75. Goldman P. Metronidazole. N Eng J Med. 1980;303:1212-8.
76. 76. Finegold SM, Mathisen GE. Metronidazole. In: Mandell R, Douglas GR Jr., Bennett JE, eds. Principles and Practice of Infectious Disease. New York: Churchill Livingston; 1990; 303-7.
77. 77. Smilack JD, Wilson WR, Cockerill FR. Tetracyclines, chloramphenicol, erythromycin, clindamycin, and metronidazole. Mayo Clin Proc. 1991;66:1270-80.
78. 78. Hamed KA, Studemeister AE. Successful response of metronidazole-resistant trichmonal vaginitis to tinidazole. A case report. Sex Trans Dis. 1992;19:339-40.
79. 79. Schmadel LK, McEvoy GK. Topical metronidazole: a new therapy for rosacea. Clin Pharm. 1990;9:94-101.
80. 80. Stoltze K, Stellfeld M. Systemic absorption of metronidazole after application of a metronidazole 25% dental gel. J Clin Periodont. 1992;19:693-7.
81. 81. Anon: Drugs for parasitic infections. Med Lett Drugs Ther. 1992;34:17-26.
82. 82. Sweet RL. New approaches for the treatment of bacterial vaginosis. Am J Obstet Gyn. 1993;169:479-82.
83. 83. Lugo-Miro VI, Green M, Mazur L. Comparison of different metronidazole therapeutic regimens for bacterial vaginosis. A meta-analysis. JAMA. 1992;268:92-5.
84. 84. Sutherland L, Singleton J, Sessions J, et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut. 1991;32:1071-5.
85. 85. Motta GJ. Topical metronidazole. Part I. Ostomy Wound Management. 1992;38:35-8.
86. 86. Dhawan VK, Thadepalli H. Clindamycin: a review of fifteen years of experience. Rev Infect Dis. 1982;4:1133-53.
87. 87. Steigbigel NH. Erythromycin, lincomycin, and clindamycin. In: Mandell R, Douglas GR Jr., Bennet JE, eds. Principles and Practice of Infectious Disease. New York: Churchill Livingston Inc.; 1990:308-17.
88. 88. Dannemann B, McCutchan JA, Israelski D, et al. Treatment of toxoplasmic encephalitis in patients with AIDS. Ann Intern Med 1992;116:33-43.
89. 89. Kay R, DuBois RE. Clindamycin/primaquine therapy and secondary prophylaxis against Pnuemocystis carinii pneumonia in patients with AIDS. South Med J. 1990;83:403-4.
90. 90. Noskin GA, Murphy RL, Black JR, et al. Salvage therapy with clindamycin/primaquine for Pneumocystis pneumonia. Clin Infect Dis. 1992;14:183-8.
91. 91. Musial CE, Rosenblatt JE. Antimicrobial susceptibilities of anaerobic bacteria isolated at the Mayo Clinic during 1982 through 1987: comparison from 1977 through 1981. Mayo Clin Proc. 1989;64:392-9.
92. 92. Cuchural GJ Jr, Tally FP, Jacobus NV, et al. Susceptibility of the Bacteroides fragilis group in the United States: analysis by site of isolation. Antimicrob Agents Chemother. 1988;32:717-22.
93. 93. Yee MH, Guiney DG, Hasegawa P, Davis CE. Clinical significance of clindamycin-resistant Bacteroides fragilis. JAMA. 1982;248:1860-3.
94. 94. Levison ME, Manfura CT, Lorber B. et al. Clindamycin compared with penicillin for the treatment of anaerobic lung abscess. Ann Intern Med. 1983;98:466-71.
95. 95. Gudiol F, Manresa F, Pallares R, et al. Clindamycin vs. penicillin for anaerobic lung infections: high rate of penicillin failures associated with penicillin-resistant Bacteroides melaninogenicus. Ann Intern Med. 1990;150:2525-9.
96. 96. Bartlett JG, Gorbach SL. Penicillin or clindamycin for primary lung abscess? (editorial) Ann Intern Med. 1983;98:546-8.
97. 97. Alger LS, Lovchik JC. Comparative efficacy of clindamycin vs. erythromycin in eradication of antenatal Chlamydia trachomatis. Am J Obstet Gynecol. 1991;165:375-81.
98. 98. Anon: Topical treatment for bacterial vaginosis. Med Lett Drugs Ther. 1992;34:109.
99. 99. Schmitt C, Sobel JD, Meriwether C. Bacterial vaginosis: treatment with clindamycin cream vs. oral metronidazole. Obstet Gynecol. 1992;79:1020-3.
100. 100. Leyden JJ, Shalita AR, Saathuan GD, et al. Erythromycin 2% gel in comparison with clindamycin phosphate 1% solution in acne vulgaris. Am J Am Acad Dermatol. 1987;16:822-7.
101. 101. Anon: Treatment of Clostridium difficile diarrhea. Med Lett Drugs Ther. 1989;31:94-5.